Zavesca User Fee Goal In August; EU Review Raises Neurotoxicity Concerns
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
European review documents for Oxford GlycoSciences/Actelion’s Gaucher disease treatment Zavesca raise two concerns that are likely issues in FDA’s review: comparative efficacy to enzyme replacement therapy and neurological adverse events.
You may also be interested in...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: